Equities

IND Swift Laboratories Ltd

INDSWFTLAB:NSI

IND Swift Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)123.10
  • Today's Change-0.90 / -0.73%
  • Shares traded432.71k
  • 1 Year change+86.66%
  • Beta-0.0614
Data delayed at least 15 minutes, as of Apr 24 2024 11:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ind-Swift Laboratories Limited is an India-based company. The Company is engaged in the business of manufacturing intermediates and formulations. The Company’s products or services include Advanced Intermediates. It is API partner for many organizations both in generic and innovative domains. The Company offers reference standards and impurities for various active pharmaceutical ingredients (APIs) under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for supply. The Company offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories.

  • Revenue in INR (TTM)11.92bn
  • Net income in INR431.95m
  • Incorporated1995
  • Employees1.50k
  • Location
    IND Swift Laboratories LtdSCO 850Shivalik Enclave, NAC, ManimajraCHANDIGARH 160101IndiaIND
  • Phone+91 1 725061850
  • Fax+91 1 722730504
  • Websitehttps://www.indswiftlabs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Wanbury Ltd5.69bn233.39m5.17bn1.58k22.18--14.300.90867.127.12173.80--------3,598,099.00--6.56----46.1543.924.104.54--1.82-----2.265.95-112.76--34.73--
ZIM Laboratories Ltd3.55bn163.97m5.42bn525.0033.07--16.231.533.363.3672.78--------6,761,375.00--3.96--7.0053.5747.554.623.93--4.08--2.4919.527.7667.935.045.16--
Medicamen Biotech Ltd1.71bn126.93m5.51bn388.0044.32--30.343.239.789.78131.89--------4,398,250.00--7.17--10.4446.8833.856.5810.87--4.76--8.6122.024.77-0.35557.98-4.210.00
Kilitch Drugs (India) Ltd1.55bn145.71m5.65bn153.0038.14--35.033.659.219.2198.24--------10,132,730.00--2.63--3.5939.6833.858.255.01--3.43--2.9322.2022.3041.8215.191.79--
Albert David Ltd3.55bn662.42m6.84bn1.27k10.32--9.301.93116.07116.07621.75--------2,791,696.00--7.61--10.1764.3360.2118.678.47--108.22--16.188.953.402.6021.826.8110.35
Valiant Laboratories Ltd-100.00bn-100.00bn6.95bn--------------------------------------------------60.35--27.66------
IND Swift Laboratories Ltd11.92bn431.95m7.31bn1.50k16.90--7.810.61357.327.32201.78--------7,966,648.00--0.5374--0.683947.6040.863.671.08--2.27--0.0016.239.542,314.8316.71-9.61--
Nectar Lifesciences Ltd16.32bn80.79m7.62bn1.59k93.19--11.060.46720.36490.364974.40--------10,271,550.00--0.0556--0.103827.4015.630.4950.0707--0.7366--32.09-8.70-4.33-196.55---1.95--
Sakar Healthcare Ltd1.51bn124.73m7.83bn297.0058.99--26.805.196.106.1073.58--------5,082,286.00--6.35--7.5946.1844.288.2610.84--2.40----4.0020.23-16.3027.3156.31--
Panacea Biotec Ltd5.52bn-119.17m8.46bn1.09k----16.441.53-1.89-1.8989.86--------5,046,990.00--10.52--18.6556.8850.87-2.2127.34------0.00-30.44-5.06-103.08--21.89--
Jagsonpal Pharmaceuticals Ltd2.21bn245.16m8.61bn940.0035.01--32.773.909.309.3083.51--------2,347,522.00--10.02--12.5154.0958.4711.118.03--30.39--36.248.7913.3341.72---39.20118.67
Bajaj Healthcare Ltd4.98bn212.66m8.80bn1.06k41.36--17.961.777.71-18.22180.50--------4,684,510.00--9.86--17.4242.2626.474.278.57--1.66-----0.970415.53-39.7323.1660.8231.95
Data as of Apr 24 2024. Currency figures normalised to IND Swift Laboratories Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.